Abdulelah Alhawsawi
CEO

Novo Genomics offers comprehensive genomic and multi-omics analysis services to provide personalized health and wellness insights. They make precision medicine accessible through genetic testing, oncology diagnostics, pharmacogenomics, prenatal screening, and rare disease diagnosis. Their offerings support individuals, clinicians, and researchers in improving health outcomes and advancing genomic studies.
Funding not disclosed

CEO
Access to advanced genomic and multi-omics analysis for personalized health and wellness solutions is often limited. This restricts the ability to leverage genetic information for early intervention, optimized treatment, and proactive health management.
Novo Genomics provides a comprehensive suite of genomic and multi-omics services, utilizing advanced analytics and data mining to deliver personalized health and wellness insights. The company focuses on making precision medicine accessible through a range of diagnostic and research support offerings. By analyzing genetic markers and molecular profiles, Novo Genomics aims to improve clinical outcomes and promote proactive health management for individuals and support research initiatives.
Primary customers include individuals seeking personalized health insights, clinicians requiring advanced diagnostics, and researchers involved in genomic and multi-omics studies.